Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · CellCept

CellCept 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7

HOS-085164 · Präparat HOS-083095

Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)

Wechselwirkungen · CellCept

CellCept 1 g/5 ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 49

HOS-085320 · Präparat HOS-083095

Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)

Wechselwirkungen · CellCept

CellCept 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 72

HOS-085392 · Präparat HOS-083095

Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)

Wechselwirkungen · Plavix

Plavix 75 mg film-coated tablets Plavix 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-087950 · Präparat HOS-083591

Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole. The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced (maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%, respectively. These results indicate that clopidogrel can be administered with pantoprazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167)

Wechselwirkungen · Iscover

Iscover 75 mg film-coated tablets Iscover 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-088001 · Präparat HOS-083599

Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole. The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced (maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%, respectively. These results indicate that clopidogrel can be administered with pantoprazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 19

HOS-114841 · Präparat HOS-094169

Antacids aluminium- and Tipranavir Cmax ↓ 25% Dosing of Aptivus, co- magnesium-based antacid Tipranavir AUC ↓ 27% administered with low dose QD ritonavir, with antacids should be Mechanism unknown separated by at least a two hours time interval. Proton pump inhibitors (PPIs) Omeprazole 40 mg QD Omeprazole Cmax ↓ 73% The combined use of Aptivus, co- Omeprazole AUC ↓ 70% administered with low dose ritonavir, with either omeprazole Similar effects were observed for or esomeprazole is not the S-enantiomer, esomeprazole. recommended (see section 4.4). If unavoidable, upward dose Induction of CYP 2C19 by adjustments for either tipranavir/r omeprazole or esomeprazole may be considered based on clinical Tipranavir ↔ response to therapy. There are no data available indicating that omeprazole or esomeprazole dose adjustments will overcome the observed pharmacokinetic interaction. Recommendations for maximal doses of omeprazole or esomeprazole are found in the corresponding product information. No tipranavir with ritonavir dose adjustment is required. Lansoprazole Based on the metabolic profiles The combined use of Aptivus, co- Pantoprazole of tipranavir/r and the proton administered with low dose Rabeprazole pump inhibitors, an interaction ritonavir, with proton pump No interaction study can be expected. As a result of inhibitors is not recommended performed CYP3A4 inhibition and (see section 4.4). If the co- CYP2C19 induction by administration is judged tipranavir/r, lansoprazole and unavoidable, this should be done pantoprazole plasma under close clinical monitoring. concentrations are difficult to predict. Rabeprazole plasma concentrations might decrease as a result of induction of CYP2C19 by tipranavir/r.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) pantoprazole (HOS-085167) ritonavir (HOS-084521) omeprazole (HOS-085912)

Wechselwirkungen · Pradaxa

Pradaxa 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 14

HOS-118663 · Präparat HOS-094855

Pantoprazole When Pradaxa was co-administered with pantoprazole, a decrease in the dabigatran AUC of approximately 30 % was observed. Pantoprazole and other proton-pump inhibitors (PPI) were co-administered with Pradaxa in clinical trials, and concomitant PPI treatment did not appear to reduce the efficacy of Pradaxa. Ranitidine Ranitidine administration together with dabigatran etexilate had no clinically relevant effect on the extent of absorption of dabigatran.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pantoprazole (HOS-085167) dabigatran (HOS-112096) ranitidine (HOS-085660)

Wechselwirkungen · Pradaxa

Pradaxa 110 mg hard capsules · Abschnitt 4.5 · PDF-Seite 47

HOS-118735 · Präparat HOS-094855

Pantoprazole When Pradaxa was co-administered with pantoprazole, a decrease in the dabigatran AUC of approximately 30 % was observed. Pantoprazole and other proton-pump inhibitors (PPI) were co-administered with Pradaxa in clinical trials, and concomitant PPI treatment did not appear to reduce the efficacy of Pradaxa. Ranitidine Ranitidine administration together with dabigatran etexilate had no clinically relevant effect on the extent of absorption of dabigatran.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pantoprazole (HOS-085167) dabigatran (HOS-112096) ranitidine (HOS-085660)

Wechselwirkungen · Pradaxa

Pradaxa 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 87

HOS-118824 · Präparat HOS-094855

Pantoprazole When Pradaxa was co-administered with pantoprazole, a decrease in the dabigatran AUC of approximately 30 % was observed. Pantoprazole and other proton-pump inhibitors (PPI) were co-administered with Pradaxa in clinical trials, and concomitant PPI treatment did not appear to reduce the efficacy of Pradaxa. Ranitidine Ranitidine administration together with dabigatran etexilate had no clinically relevant effect on the extent of absorption of dabigatran.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pantoprazole (HOS-085167) dabigatran (HOS-112096) ranitidine (HOS-085660)

Wechselwirkungen · Pradaxa

Pradaxa 20 mg coated granules Pradaxa 30 mg coated granules Pradaxa 40 mg coated granules Pradaxa 50 mg coated granules Pradaxa 110 mg coated granules Pradaxa 150 mg coated granules · Abschnitt 4.5 · PDF-Seite 121

HOS-118910 · Präparat HOS-094855

Pantoprazole When Pradaxa was co-administered with pantoprazole, a decrease in the dabigatran AUC of approximately 30 % was observed. Pantoprazole and other proton-pump inhibitors (PPI) were co-administered with Pradaxa in clinical trials, and concomitant PPI treatment did not appear to reduce the efficacy of Pradaxa. Ranitidine Ranitidine administration together with dabigatran etexilate had no clinically relevant effect on the extent of absorption of dabigatran.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pantoprazole (HOS-085167) dabigatran (HOS-112096) ranitidine (HOS-085660)

Wechselwirkungen · Mycophenolate mofetil Teva

Mycophenolate mofetil Teva 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7

HOS-209308 · Präparat HOS-154301

Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co- administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)

Wechselwirkungen · Mycophenolate mofetil Teva

Mycophenolate mofetil Teva 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29

HOS-209387 · Präparat HOS-154301

Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)

Wechselwirkungen · Myfenax

Myfenax 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7

HOS-209458 · Präparat HOS-154315

Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co- administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)

Wechselwirkungen · Myfenax

Myfenax 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29

HOS-209526 · Präparat HOS-154315

Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co- administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)

Wechselwirkungen · Clopidogrel Zentiva (previously Clopidogrel Winthrop)

Clopidogrel Zentiva 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8

HOS-209894 · Präparat HOS-154399

7 Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole. The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced (maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%, respectively. These results indicate that clopidogrel can be administered with pantoprazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167)

Gegenanzeigen · Pantozol Control

PANTOZOL Control 20 mg gastro-resistant tablets · Abschnitt 4.3 · PDF-Seite 3

HOS-121264 · Präparat HOS-095311

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Pantozol Control

PANTOZOL Control 20 mg gastro-resistant tablets · Abschnitt 4.3 · PDF-Seite 3

HOS-121265 · Präparat HOS-095311

Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, nelfinavir; due to significant reduction in their bioavailability (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) nelfinavir (HOS-084520) protease (HOS-085623)

Wechselwirkungen · Pantozol Control

PANTOZOL Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5

HOS-121266 · Präparat HOS-095311

Medicinal products with pH-dependent absorption pharmacokinetics

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Pantozol Control

PANTOZOL Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5

HOS-121267 · Präparat HOS-095311

PANTOZOL Control may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g., ketoconazole).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513)

Wechselwirkungen · Pantozol Control

PANTOZOL Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5

HOS-121268 · Präparat HOS-095311

HIV protease inhibitors

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623)